STX209: Phase IIb data

The double-blind, U.S. Phase IIb Study 209AS208 in 150 patients ages 5 to 21 years with ASD showed that oral STX209 for 12 weeks missed the primary endpoint of reducing patient-rated ABC-LSW subscale scores